Paul Spence
Corporate Officer/Principal bei OPTINOSE, INC.
Vermögen: 228 671 $ am 30.04.2024
Profil
Paul Spence is currently the Chief Commercial Officer at OptiNose, Inc. He previously worked as the Executive Director-Go to Market Models at Boehringer Ingelheim Pharmaceuticals, Inc. and as the Vice President-US Commercial at Nestle Health Science SA from 2016 to 2019.
From 2020 to 2022, he was the Senior VP & Chief Commercial Officer-US at Aimmune Therapeutics, Inc. Mr. Spence received his undergraduate degree from The Pennsylvania State University and his MBA from Villanova University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
OPTINOSE, INC.
0,22% | 28.02.2024 | 252 675 ( 0,22% ) | 228 671 $ | 30.04.2024 |
Aktive Positionen von Paul Spence
| Unternehmen | Position | Beginn |
|---|---|---|
| OPTINOSE, INC. | Corporate Officer/Principal | 15.12.2022 |
Ehemalige bekannte Positionen von Paul Spence
| Unternehmen | Position | Ende |
|---|---|---|
| AIMMUNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2022 |
Nestle Health Science SA
 Nestle Health Science SA Pharmaceuticals: OtherHealth Technology Nestle Health Science SA develops nutritional therapies. Its health management services include aging, brain health, chronic medical conditions, critical care and surgery, food allergy, gastro intestinal, metabolic diseases, and obesity pediatrics. The company was founded in 2011 and is headquartered in Vevey, Switzerland. | Corporate Officer/Principal | 01.01.2019 |
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Corporate Officer/Principal | - |
Ausbildung von Paul Spence
| Villanova University | Masters Business Admin |
| The Pennsylvania State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| OPTINOSE, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Nestle Health Science SA
Nestle Health Science SA Pharmaceuticals: OtherHealth Technology Nestle Health Science SA develops nutritional therapies. Its health management services include aging, brain health, chronic medical conditions, critical care and surgery, food allergy, gastro intestinal, metabolic diseases, and obesity pediatrics. The company was founded in 2011 and is headquartered in Vevey, Switzerland. | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
